Precipio, Inc.(PRPO)

6.19-0.25-3.85%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Precipio Third Quarter 2024 Earnings: US$0.42 loss per share (vs US$1.04 loss in 3Q 2023)
  Simply Wall St. · 11-09
  Precipio Third Quarter 2024 Earnings: US$0.42 loss per share (vs US$1.04 loss in 3Q 2023)
- Precipio Announces Q3-2024 Shareholder Update Call
  GlobeNewswire · 11-07
  Precipio Announces Q3-2024 Shareholder Update Call
- Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
  GlobeNewswire · 10-08
  Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
- Precipio Announces Employee Stock Option Plan Repricing
  THOMSON REUTERS · 09-07
  Precipio Announces Employee Stock Option Plan Repricing
- Precipio- Repricing Stock Options Granted Prior to Year-End 2022, Representing About 58% of Total Outstanding Options
  THOMSON REUTERS · 09-07
  Precipio- Repricing Stock Options Granted Prior to Year-End 2022, Representing About 58% of Total Outstanding Options
- Precipio Inc - Options Granted in 2023 and in 2024 Will Remain Unaltered
  THOMSON REUTERS · 09-07
  Precipio Inc - Options Granted in 2023 and in 2024 Will Remain Unaltered
- Precipio Announces Employee Stock Option Plan Repricing
  GlobeNewswire · 09-07
  Precipio Announces Employee Stock Option Plan Repricing
- Zacks Initiates Coverage of Precipio With Outperform Recommendation
  Zacks · 09-05
  Zacks Initiates Coverage of Precipio With Outperform Recommendation
- Precipio GAAP EPS of -$0.83, revenue of $4.44M
  seekingalpha · 08-20
  Precipio GAAP EPS of -$0.83, revenue of $4.44M
- Precipio Announces Q2-2024 Shareholder Update Call
  GlobeNewswire · 08-16
  Precipio Announces Q2-2024 Shareholder Update Call
- Press Release: Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven
  Dow Jones · 07-25
  Press Release: Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven
- Precipio Reports Q2 2024 Revenue Of $4.4M Vs $4.33M Est; Expects Pathology Division's Revenues Will Reach More Than $1.5M Per Month By Year End
  Benzinga · 07-17
  Precipio Reports Q2 2024 Revenue Of $4.4M Vs $4.33M Est; Expects Pathology Division's Revenues Will Reach More Than $1.5M Per Month By Year End
- Precipio Reports $4.4M for Q2-2024 (Unaudited) Revenues, a Leap of 30% From Q1-2024
  THOMSON REUTERS · 07-17
  Precipio Reports $4.4M for Q2-2024 (Unaudited) Revenues, a Leap of 30% From Q1-2024
- Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024
  GlobeNewswire · 07-17
  Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024
- Press Release: Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders
  Dow Jones · 06-14
  Press Release: Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders
- Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
  GlobeNewswire · 06-13
  Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
- Precipio Provides Status Update on Current Business Matters
  THOMSON REUTERS · 06-12
  Precipio Provides Status Update on Current Business Matters
- Precipio Provides Status Update on Current Business Matters
  GlobeNewswire · 06-12
  Precipio Provides Status Update on Current Business Matters
Company Profile
Company Name
Precipio, Inc.
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.precipiodx.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
- 11-12
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 11-07
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 11-06
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 09-06
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 08-15
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 08-14
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 08-02
  Beneficial Ownership Change
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
  Form SC 13G - Statement of Beneficial Ownership by Certain Investors
- 06-25
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-14
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 05-06
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-01
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 03-29
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 03-29
  Annual Report
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 03-26
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 01-03
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report

1D
5D
Day
Week
Month

High

6.25

Open

6.25

Volume%

0.23

Low

6.19

6.44

T/O Rate

0.05%

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

Precipio, Inc.(PRPO)

Company Profile

Most Discussed